Updated data from Ph 2 DeFianCe study of sirexatamab (DKN-01) + bevacizumab and chemo combo shows statistically significant PFS improvements in DKK1-high, VEGF-naïve and liver mets MSS colorectal cancer patients July 1, 2025
Positive OS Data for Atebimetinib (IMM-1-104) from Ph 2a Trial in 1L Pancreatic Cancer Patients Reported June 24, 2025
Zanzalintinib + Tecentriq Combination Improved OS in STELLAR-303 Ph 3 Pivotal Trial in Patients with Metastatic CRC June 24, 2025
FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations June 24, 2025
FDA grants Orphan Drug Designation to ADoBind MC001 for the treatment of pancreatic cancer June 24, 2025
Positive Biomarker and Machine Learning Data from Ph 2 Elraglusib Trial in 1L Treatment of Metastatic Pancreatic Cancer Announced June 24, 2025
First Patient dosed in Ph 1 Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC) June 17, 2025
Ph 3 Data for Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet June 17, 2025
Nadunolimab awarded US FDA Fast Track Designation for the treatment of patients with metastatic PDAC with high IL1RAP expression levels June 17, 2025
FDA authorizes Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers June 17, 2025
CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the 1L Treatment of Gastric/GEJ Cancer June 17, 2025
CHM CDH17 granted Fast Track for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) June 11, 2025
Tempest Receives Orphan Drug Designation from the EMA for Amezalpat for the Treatment of Patients with HCC June 10, 2025
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for CLDN18.2-targeting ADC XNW27011 June 3, 2025
NMPA Approves Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer June 3, 2025
Positive Results from Ph 3 TALENTACE Study of Tecentriq and Avastin for Unresectable HCC announced May 27, 2025
NMPA CDE grants Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC May 27, 2025
IDeate-Esophageal01 Ph 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma May 21, 2025
